Corporate profile

Home > Corporate profile

Corporate profile

Overview

Company nameTMRC Co., Ltd.
Location of head officeMI Bldg.,
1-12-12, KitaShinjuku, Shinjuku-ku, Tokyo 169-0074, JAPAN  <Map>
Board Directors
Hirobumi TakeuchiPresident and CEO
Masaki SudoBoard Director
Katsuhiro UtoBoard Director
EstablishedJanuary 2002

page top

History

2002JanuaryEstablished in Minato-ku, Tokyo, as a Contract Research Organization (CRO) specializing in the field of cancer.
2004FebruaryObtained a license for Tamibarotene, and started an R&D business.
2009MarchSpun off CRO business and established it as a subsidiary company, then transferred 100% of stocks to Sugi Medical Co., Ltd.
2014JuneGranted a license for Tamibarotene, for the treatment of Pediatric cancer, to a Japanese company Ohara Pharmaceutical Co., Ltd. in Japanese territory.
 JulyReached an agreement with Children's Hospital Los Angeles (CHLA *) to develop and commercialize TM-411 in neutropenia.
2015SeptemberGranted a license for Tamibarotene, for the treatment of cancer, to a US company Syros Pharmaceuticals Inc., in North American and European territory.
2017FebruaryAffiliated under RaQualia Pharma Inc. as wholly owned subsidiary
2021JanuaryGranted a license for the Biomarker Patent in the Asian territory from Syros Pharmaceuticals Inc.

*Children's Hospital Los Angeles has been named the best children's hospital on the West Coast and among the top five in the nation for clinical excellence with its selection to the prestigious U.S. News & World Report Honor Roll. Children's Hospital is home to The Saban Research Institute, one of the largest and most productive pediatric research facilities in the United States. Children's Hospital is also one of America's premier teaching hospitals through its affiliation since 1932 with the Keck School of Medicine of the University of Southern California.

page top

Board Directors

under construction

page top

Management Team

under construction

page top